Myo or D-Chiro Inositol for PMOS? The Ratio Is the Whole Story

You stand in front of the supplement shelf — or the fourteenth browser tab — and the bottles disagree with each other. One is pure myo-inositol. One is pure D-chiro. One says 40:1. One says 2:1 and calls itself "advanced." They all cite studies. They cannot all be right.

Inositol is the most evidence-supported supplement for PCOS — now PMOS, after a 2026 Lancet consensus — so the confusion is worth clearing up properly. The short version: the two inositols do different jobs, the body keeps them in a specific balance, and for most people the ratio matters more than the dose. The longer version is where the marketing tends to get it wrong.

Why there are two inositols at all

Inositol comes in two forms that matter here. Myo-inositol carries the signal that helps the ovary respond to FSH and take up glucose. D-chiro-inositol acts downstream of insulin, helping store glucose as glycogen. Your body makes D-chiro from myo on demand, and insulin is the enzyme that drives that conversion.

Most tissues hold the two at roughly 40:1, myo to D-chiro. The ovary runs even more myo-heavy — closer to 100:1 in healthy follicular fluid. That tilt is not an accident. The egg's local environment depends on myo-inositol.

Here is where PMOS complicates things. When insulin runs high — as it does in most people with the condition — it speeds up the myo-to-D-chiro conversion inside the ovary. Myo gets depleted exactly where it's needed, while D-chiro accumulates. The follicular ratio can flip almost completely. So the problem in the ovary isn't too little D-chiro. It's too little myo.

Why more D-chiro can backfire

This is the part the "advanced, high-strength D-chiro" bottles skip. If the ovary is already over-converting myo into D-chiro, pouring in more D-chiro can push the local balance further in the wrong direction. A 2019 study that compared seven different myo-to-D-chiro ratios found 40:1 restored ovulation best — and that higher D-chiro proportions performed worse, not better. The intuition that "more of the active one" helps doesn't hold here.

A 2026 mouse study adds a mechanistic footnote. D-chiro on its own grew larger follicles early — at days six to eight — but the advantage wasn't maintained by day ten. A fast start that doesn't last is consistent with what the ratio research has been saying: D-chiro has a role, but it isn't the lever you lean on alone.

What the evidence actually shows — and doesn't

Time for the honest summary, because inositol is good but it isn't magic. The systematic review that informed the 2023 International Guideline update pooled the trials and landed somewhere reasonable: inositol shows benefits for some metabolic measures, a possible ovulation benefit, and no clear effect on several other outcomes. The quality of the underlying studies is mixed. Anyone telling you inositol reliably fixes everything is ahead of the data.

What does hold up well is cycle regularity and tolerability. In the pooled trials, myo-inositol came out roughly non-inferior to metformin for restoring menstrual cycles — around 1.8 times the cycle-regularity rate of placebo — without metformin's stomach trouble. That combination, a real effect plus an easy side-effect profile, is why it earns a default slot in most PMOS plans even with the honest hedges attached.

So what ratio, what dose, how long

For most people, the evidence points to a 40:1 myo-to-D-chiro blend — the same balance most of your tissues maintain. In practice that's about 2,000 mg of myo-inositol with 50 mg of D-chiro, taken twice a day. The trials that show benefit generally ran for at least three months, which fits the biology: an egg takes about 90 days to mature, so a supplement working at the follicular level needs a full cycle of follicles to show its hand. Judging it at three weeks tells you nothing.

A few honest caveats. The 40:1 figure comes mostly from trials in classic, insulin-resistant presentations; whether a different ratio suits the lean subtype, where insulin resistance is subtler, is still an open question. And inositol is a supplement, not a substitute for a workup — if your cycles or androgens are the issue, the bloodwork still matters.

Where to start

If you only ever try one supplement for PMOS, the evidence points here — and the practical takeaway is unglamorous: a plain 40:1 blend at the studied dose, given a real three months, beats a clever-sounding high-D-chiro product. We covered where inositol sits relative to other options in our guide to PMOS supplements by subtype.

Before you build a supplement plan, it helps to know which version of PMOS you're working with — the metabolic, hyperandrogenic, anovulatory, and SHBG-dominant subtypes don't all respond the same way. Our free 10-minute assessment walks through your symptom pattern and shows you where you stand, without asking for anything in return.

Citations

• Teede HJ, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026 May 12.
• Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. J Clin Endocrinol Metab. 2024;109(6):1630.
• Nordio M, et al. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019.
• Update on the combination of myo-inositol/D-chiro-inositol for the treatment of polycystic ovary syndrome. Gynecol Endocrinol. 2024.
• Myo- versus D-chiro-inositol in follicular development (murine model). PLOS One. 2026.